GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » Current Ratio

AgeX Therapeutics (AgeX Therapeutics) Current Ratio : 0.13 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. AgeX Therapeutics's current ratio for the quarter that ended in Dec. 2023 was 0.13.

AgeX Therapeutics has a current ratio of 0.13. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If AgeX Therapeutics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for AgeX Therapeutics's Current Ratio or its related term are showing as below:

AGE' s Current Ratio Range Over the Past 10 Years
Min: 0.13   Med: 0.43   Max: 5.79
Current: 0.13

During the past 7 years, AgeX Therapeutics's highest Current Ratio was 5.79. The lowest was 0.13. And the median was 0.43.

AGE's Current Ratio is ranked worse than
95.54% of 1548 companies
in the Biotechnology industry
Industry Median: 3.795 vs AGE: 0.13

AgeX Therapeutics Current Ratio Historical Data

The historical data trend for AgeX Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AgeX Therapeutics Current Ratio Chart

AgeX Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 1.23 0.43 0.25 0.24 0.13

AgeX Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.08 0.06 0.36 0.13

Competitive Comparison of AgeX Therapeutics's Current Ratio

For the Biotechnology subindustry, AgeX Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgeX Therapeutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where AgeX Therapeutics's Current Ratio falls into.



AgeX Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

AgeX Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=0.754/5.914
=0.13

AgeX Therapeutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=0.754/5.914
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AgeX Therapeutics  (AMEX:AGE) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


AgeX Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AgeX Therapeutics (AgeX Therapeutics) Business Description

Traded in Other Exchanges
Address
1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.
Executives
Jean-christophe Renondin director 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp. director, 10 percent owner 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett director C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae officer: Chief Financial Officer C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May director 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West director, officer: Chief Executive Officer AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall officer: Corporate Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg officer: Vice President-Research 935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin director 3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd 10 percent owner 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik officer: Chief Operating Officer C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501